SPRY
ARS Pharmaceuticals, Inc.
Industry
Biotechnology
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Loading...
Open
15.64
Mkt cap
1.6B
Volume
570K
High
16.24
P/E Ratio
-34.34
52-wk high
17.08
Low
15.28
Div yield
N/A
52-wk low
3.38

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.